Markets:

Overview

News

Currencies

International

Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

13.29 +0.39 (+3.06%)

Streaming Delayed Price Updated: 9:48 AM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about EyePoint, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Topics Regulatory Compliance

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

Via The Motley Fool

Topics Regulatory Compliance

EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss ↗

March 04, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Analyst Expectations For EyePoint Pharmaceuticals's Future ↗

May 29, 2025

Via Benzinga

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗

March 15, 2026

EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.

Via The Motley Fool

EyePoint (EYPT) Q4 2025 Earnings Call Transcript ↗

March 04, 2026

EyePoint (EYPT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

A Peek at EyePoint Pharmaceuticals's Future Earnings ↗

May 06, 2025

Via Benzinga

Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews ↗

March 06, 2025

Via Benzinga

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...

Via MarketMinute

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles

January 08, 2026

In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens

January 02, 2026

As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU

January 01, 2026

As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy

December 31, 2025

As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

EyePoint (EYPT) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

EyePoint (EYPT) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss ↗

November 05, 2025

EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data.

Via Chartmill

Topics Earnings

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 15, 2025

Via Benzinga

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study ↗

October 15, 2025

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

Via Benzinga

EyePoint (EYPT) Q2 Revenue Drops 44% ↗

August 06, 2025

Via The Motley Fool

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market ↗

August 06, 2025

EyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid...

Via Chartmill

Topics Earnings

Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals ↗

June 17, 2025

Via Benzinga

Breakout Momentum Plays You May Not Know About

June 06, 2025

Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.

Via MarketBeat

Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗

May 28, 2025

Via Benzinga

Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

March 14, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.